Inhibikase Therapeutics (IKT) and The Competition Critical Survey

Inhibikase Therapeutics (NASDAQ:IKT) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Inhibikase Therapeutics to similar businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Inhibikase Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1	2	4	3	2.90
Inhibikase Therapeutics Competitors	7820	13783	25790	1035	2.41

Inhibikase Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 210.46%. As a group, “Pharmaceuticals” companies have a potential upside of 24.58%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than its rivals.

Valuation & Earnings

This table compares Inhibikase Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	-$48.26 million	-3.82
Inhibikase Therapeutics Competitors	$3.54 billion	$3.17 billion	553.74

Inhibikase Therapeutics’ rivals have higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Inhibikase Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-40.53%	-38.44%
Inhibikase Therapeutics Competitors	-2,393.19%	-220.45%	-16.12%

Institutional & Insider Ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Inhibikase Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics’ rivals have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.